FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	

3235-0287 OMB Number: Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					or	Secti	on 30(h)	of the	Ínvestment	Con	npany Act	of 1940							
1. Name and Address of Reporting Leison					2. Issuer Name and Ticker or Trading Symbol ZIOPHARM ONCOLOGY INC [ZIOP]								ck all appli	,					
	(Fi RD SECUI OVE AVEI	RITY, LLC	(Middle)		09/	Date of Earliest Transaction (Month/Day/Year) 1/29/2017 If Amendment, Date of Original Filed (Month/Day/Year)						6. Inc	below)		o Filin	Other (: below)			
(Street)	RD V	A	24141				anonamong data ar original rinda (moranizas), roar,					Line)					n		
(City)	(S	tate)	(Zip)																
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					ar)	2A. Deemed Execution Date, f any Month/Day/Year		Transaction Disp Code (Instr. 5)		Dispose	urities Acquired (A sed Of (D) (Instr. 3,			Securiti Benefic	5. Amount of Securities Beneficially Owned Following		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
						Code V Amount (A) or (D)						rice	Transac (Instr. 3	tion(s)			(111511.4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security (Instr. 3) 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) (Month/Day/Year) 3. Transaction Date (Month/Day/Year) 4. Transaction Date (Month/Day/Year) 3. Transaction Date (Month/Day/Year)					tive ties ed	6. Date Exe Expiration (Month/Day		7. Title ar Amount of Securitie Underlyin Derivativ (Instr. 3 a	of s ng e Seci		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)				
					Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	or	ount nber res					
Series 1 Preferred Stock	(1)	09/29/2017			J		1,149		(1)		(1)	Common Stock	(1)	(2)	116,127	(2)	I	by Intrexon ⁽³⁾
	nd Address of	Reporting Person*																	

1. Name and Address of Reporting Person*									
KIRK RANDAL J									
(Last)	(First)	(Middle)							
C/O THIRD SECURITY, LLC									
1881 GROVE AVENUE									
(Street)									
RADFORD	VA	24141							
(City)	(State)	(Zip)							
1. Name and Address of Reporting Person*									
INTREXON CORP									
(Last)	(First)	(Middle)							
C/O LEGAL DEPARTMENT									
20374 SENECA MEADOWS PARKWAY									
(Street)									
GERMANTOWN	N MD 20876								
(City)	(State) (Zip)								

Explanation of Responses:

1. Each share of Series 1 Preferred Stock ("Preferred Stock") has a stated value of \$1,200, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other recapitalization with respect to the shares of Preferred Stock. The shares of Preferred Stock shall automatically convert into shares of the issuer's common stock upon the date of commercialization of a product pursuant to the collaboration between Intrexon Corporation ("Intrexon") and the issuer, subject to conversion limitations set forth in the Securities Issuance Agreement entered into between the issuer and Intrexon on June 29, 2016 (the "Issuance Agreement"). The conversion price in connection with such automatic conversion shall be determined as set forth in the Amended and Restated Certificate of Designation, Preferences and Rights of Series 1 Preferred Stock, which the issuer has filed as an exhibit to its Amendment to Current Report on Form 8-K/A, dated July 1, 2016.

2. Intrexon received the shares of Preferred Stock as payment-in-kind dividends in connection with its ownership of shares of Preferred Stock. The holders of Preferred Stock are entitled to receive a monthly

dividend payable in additional shares of Preferred Stock equal to \$12.00 per share of Preferred Stock per month (subject to adjustment), divided by the stated value of \$1,200, rounded down to the nearest whole share.

3. Randal J. Kirk, directly and through certain affiliates, is the largest shareholder of Intrexon and serves as Intrexon's Chairman of the Board and Chief Executive Officer. Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

<u>/s/ Randal J. Kirk</u> 09/29/2017 <u>/s/ Randal J. Kirk, CEO of</u>

** Signature of Reporting Person

Intrexon Corporation 09/29/2017

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.